MedTrace Logo

Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction

NCT00712101 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1912

Last updated 2011-04-20

No results posted yet for this study

Summary

The purpose of this study is to examine whether intracoronary abciximab bolus application with subsequent 12 hour intravenous infusion in addition to primary percutaneous coronary intervention is beneficial for patients with STEMI in comparison to standard i.v. bolus application with respect to 90-day mortality, reinfarction and new congestive heart failure.

Conditions

  • ST-elevation Myocardial Infarction

Interventions

DRUG

abciximab intracoronary

administer abciximab bolus intracoronary during primary percutaneous coronary intervention

DRUG

abciximab intravenously

administer abciximab bolus intravenously during primary percutaneous coronary intervention

Sponsors & Collaborators

  • University of Leipzig

    lead OTHER

Principal Investigators

  • Holger Thiele, MD, PhD · Heart Center Leipzig - University Hospital

  • Gerhard Schuler, MD, PhD · Heart Center Leipzig - University Hospital

  • Jochen Woehrle, MD, PhD · University of Ulm

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00712101 on ClinicalTrials.gov